Citi raised the firm’s price target on Krystal Biotech (KRYS) to $371 from $336 and keeps a Buy rating on the shares post the Q4 report. The firm cites higher Vyjuvek sales estimates for the target boost.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech Earnings Call Highlights Profitable Growth
- Krystal Biotech: Strong Vyjuvek Momentum, Robust Balance Sheet, and Late-Stage Pipeline Upside Support Buy Rating
- Krystal Biotech price target raised to $371 from $310 at Jefferies
- Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
- Krystal Biotech reports Q4 EPS $1.70, consensus $1.61